Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Classical inotropes and new cardiac enhancers.

John T Parissis1, Dimitrios Farmakis, Markku Nieminen

  • 1Heart Failure Unit, Attikon University Hospital, Athens, Greece. jparissis@yahoo.com

Heart Failure Reviews
|May 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac Implantable Electronic Devices in Oncology Patients: Challenges and Management.

Journal of cardiovascular electrophysiology·2026
Same author

GLP-1 Receptor Agonists: From Glycaemic Control to Cardio-Reno-Metabolic Disease Modification.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Ferroptosis-Associated Fibroblast Activation and Transcriptional Remodelling in Human Heart Failure: A Proof-of-Concept Study.

European journal of clinical investigation·2026
Same author

Evaluation and management of recent onset cardiomyopathy in the current era of heart failure therapeutics: a clinical consensus statement of the Heart Failure Association of the ESC.

ESC heart failure·2026
Same author

Sodium-glucose cotransporter 2 inhibitors across cardio-reno-metabolic disease and body mass index: a meta-analysis of randomized controlled trials.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Early Recovery of Oxygen Kinetics in Heart Failure: A Systematic Review of Oxygen Kinetics During the First Minute of Recovery after Cardiopulmonary Exercise Testing in Heart Failure.

Current cardiology reviews·2026

Acute heart failure exacerbations require careful treatment. While traditional inotropes offer temporary relief, they increase long-term mortality risk, necessitating further research into safer alternatives like levosimendan.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acute heart failure syndromes encompass various conditions, predominantly chronic heart failure exacerbations.
  • Pathophysiological mechanisms like hypotension, renal impairment, and myocardial injury negatively impact patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of classical inotropes and levosimendan in treating acute heart failure.
  • To compare the long-term mortality and clinical outcomes associated with these treatments.

Main Methods:

  • Review of existing evidence and guidelines (ESC AHF guidelines) for acute heart failure treatment.
  • Analysis of randomized trials comparing levosimendan with placebo or dobutamine.

Main Results:

  • Classical inotropes (beta-agonists, phosphodiesterase inhibitors) provide temporary hemodynamic improvement but are linked to increased long-term mortality.

Related Experiment Videos

  • Levosimendan shows potential in improving cardiac efficiency and reducing congestion without increasing myocardial oxygen demand.
  • Recent trials indicate levosimendan is not superior to placebo or dobutamine for 1- and 6-month mortality, despite a greater reduction in neurohormonal response.

    • Conclusions:

    • Classical inotropes should be used cautiously as temporary measures under strict criteria for acute heart failure exacerbations.
    • Levosimendan's role requires further investigation regarding patient selection, optimal dosing, and long-term effects before it can be considered first-line therapy.